Navigation Links
Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease

FORT LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Neurologix, Inc. (OTCBB:NRGX) today announced the publication in the June 23 issue of the journal The Lancet of positive results from the first ever gene therapy trial for Parkinson's disease and the first report of direct gene transfer into a patient's own brain cells for any adult neurodegenerative disease.

The open label Phase 1 study, conducted in 12 patients with advanced Parkinson's disease demonstrated both a lack of adverse events related to the gene therapy procedure and statistically significant improvements from baseline in both clinical symptoms and abnormal brain metabolism (as measured by positron emission tomography, or PET scanning). Although all patients had symptoms on both sides of the body, the procedure was performed on only one side of the brain, enabling the untreated side to serve as a study control. The reported improvements were observed primarily on the treated side of the body beginning three months after the gene therapy procedure and persisted through the 12 months formal study period.

Neurologix sponsored the study as part of its ongoing efforts to develop this and other gene therapy approaches to the treatment of neurodegenerative and metabolic diseases. Principal investigators Michael G. Kaplitt, MD, PhD, and Matthew J. During, MD, PhD, performed the procedures at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. Andrew Feigin, MD and David Eidelberg, MD of the Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System performed the clinical evaluations and the PET scans. Neurologix scientists were also co-investigators in the study.

"This ground-breaking study represents not only an encouraging first step in the development of a promising new approach to Parkinson's disease therapy, but also provides a platform to translate a variety of new gene therapy agents into human clinical
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:3/3/2015)... 03, 2015 Research and Markets ( ... "Global POC Diagnostics Market 2015-2019" report to their ... Global POC Diagnostics market to grow at a CAGR ... POC diagnostics are IVD devices and tools used ... setting. The use of these devices helps in the ...
(Date:3/3/2015)... 2015  Columbia Laboratories, Inc. (Nasdaq: CBRX ... a specialty pharmaceutical company focused on pharmaceuticals for women,s ... 27th Annual ROTH Conference, which will take place from ... Dana Point, California . Management,s presentation will ... Pacific Time (12:00 p.m. Eastern Time) in the Promenade ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research ... announced the addition of the "Global Ultrasound ... , The Global Ultrasound ... 5.79% over the period 2014-2019 Ultrasound ... sound waves. Ultrasound systems are extensively used by ...
Breaking Medicine Technology:Global POC Diagnostics Market 2015-2019 with Abbott Labs, Alere, Bayer Healthcare, Danaher, F. Hoffmann-La Roche & Johnson & Johnson Dominating 2Global Ultrasound Equipment Market 2015-2019: Rise in Number of MI Diagnostic Procedures with GE Healthcare, Phillips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2
... and Safety of ,First Generation, Antisense, BERKELEY ... GNTA ) announced the presentation of new data ... can be safely administered in high doses by ... presented by Dr. Anthony Tolcher, Director,of Clinical Research, ...
... Improvement in Hemodynamics and Delay Disease Progression -, ... Inc.,today announced positive results from two trials demonstrating ... a combination therapy,for the treatment of pulmonary arterial ... when given in combination with sildenafil,is well-tolerated and ...
Cached Medicine Technology:Genasense(R) Can be Administered by Brief High-Dose IV Infusion 2Genasense(R) Can be Administered by Brief High-Dose IV Infusion 3Genasense(R) Can be Administered by Brief High-Dose IV Infusion 4Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 2Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 3
(Date:3/3/2015)... Ann Arbor, MI (PRWEB) March 03, 2015 ... on NPR News Morning Edition, science correspondent Shankar Vedantam ... the University of Pennsylvania about the drastic decrease in hand-hygiene ... shift. He suggested that the problem could be solved in ... to perform hand hygiene when they enter and exit a ...
(Date:3/3/2015)... 3, 2015) (PRWEB) March 03, 2015 ... an innovator in the travel industry for the past ... expansion plan. To fulfill his vision for the future ... 400 fun, exciting and well-compensated positions as travel sales ... news sales center planned for the Boynton Beach, Florida ...
(Date:3/3/2015)... Retrofit , the comprehensive weight ... corporations, today announces the appointment of its new chief ... Mary Pigatti has recruited technology, healthcare and ... for the fast-growing company, which was recently named one ... 2015. , “Retrofit is thrilled to announce this new ...
(Date:3/3/2015)... March 03, 2015 According to ... http://www.idataresearch.com ), market saturation has made neurosurgery navigation ... the United States. Unit sales growth moderately increased ... as facilities replace older systems, and as new ... market is very much a replacement and upgrade ...
(Date:3/3/2015)... MA (PRWEB) March 03, 2015 The ... transformed the science of the little-known and incurable disease, ... its #CureFSHD campaign . The purpose of the ... FSHD, one of the most common forms of muscular ... off the campaign, today the FSH Society will begin ...
Breaking Medicine News(10 mins):Health News:BIOVIGIL Hygiene Technologies Answers Call for Hand Hygiene Alerts on Badges 2Health News:BIOVIGIL Hygiene Technologies Answers Call for Hand Hygiene Alerts on Badges 3Health News:First Class Vacations, Inc. Expansion Plan Creates 400 Jobs In South Florida 2Health News:First Class Vacations, Inc. Expansion Plan Creates 400 Jobs In South Florida 3Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 2Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 3Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 4Health News:Neurosurgery Navigation System Market Reaches Saturation in the United States 2Health News:Neurosurgery Navigation System Market Reaches Saturation in the United States 3Health News:Share to be Aware: FSH Society Launches #CureFSHD Campaign 2Health News:Share to be Aware: FSH Society Launches #CureFSHD Campaign 3
... has had a fascinating journey and as they wrap up the ... Blues, it is time for introspection for Bobby Gillespie. The band's ... // ,But after that there was a time when their ... that the "heroin hell" kicked in and it was such a ...
... The exposed super model and ramp queen Kate Moss has ... about getting exposed by the media about her cocaine addiction. // ... Kate Moss is very close to him and he has known ... said to him that it made her face the reality and ...
... from the University of Melbourne and La Trobe University have ... grains such as wheat and barley. With the stress being ... that this discovery would allow them to manipulate the fibre ... the production of beta-glucans, which is a major part of ...
... go on Phase I trial. It maybe as early as ... Shaw. ,Ms.Shaw was speaking at the conference ... for innovation and R&D.// There are close to 34 million ... always bear this in mind and develop products accordingly. ...
... Briton underwent a successful life-changing operation in India and returned ... for being// overweight. ,David Rogers, 62, from Abbeydale, ... overweight for the double hip and knee replacements that he ... he was about 37 kg too heavy for the surgery. ...
... found with breast tumors can predict the outcomes of the ... appearing in he April 1 issue of Clinical Cancer Research, ... risk for an early relapse of breast cancer. ... a potential marker of relapse in hormone-receptor positive breast cancer ...
Cached Medicine News:Health News:Overweight Briton Underwent Successful Surgery In India Being Denied By NHS 2
... series SV stereomicroscopes are of ... to their mature modular design ... job in hand. This is ... demanding routine applications will appreciate, ...
6.3X Zoom Ratio - Boasting magnifications from 0.8X to 5X, the twin zooming objective optical system developed exclusively by Nikon provides a zoom ratio of 6.3:1. Clickstops at 1X intervals allow ob...
10:1 Zoom Ratio - The parallel optical system of the SMZ-1000 has a 10:1 zoom with clickstops at 1X intervals. It features a zoom range of 0.8X to 8.0X and total magnification (depending on eyepieces...
Fixed Versatility - With a diverse selection of body tubes, stands, lighting techniques and Nikon's world-renowned optics, this modular microscope can be configured to fit nearly any application....
Medicine Products: